Background Circulating tumour cells (CTCs) are promising minimally invasive biomarkers of tumour dissemination and disease biology, but low abundance and phenotypic heterogeneity make them challenging to isolate, particularly in non-small cell lung cancer (NSCLC). Physical cell-selection approaches based on size and de...
Volga M. Saini, E. Oner, C. Cahill et al.· The journal of liquid biopsy· 0 citations
INTRODUCTION
The tumor suppressor TP53 is the most frequently mutated gene in human cancer, and drugs targeting specific mutant p53 proteins have been developed. Rezatapopt, which reactivates the Y220C p53 protein, was recently evaluated in the Phase I PYNNACLE trial in patients with solid tumors, with promising result...
M. Molina-Vila, Z. Tsourti, A. Stenzinger et al.· Journal of Thoracic Oncology· 0 citations
Abstract Motivation Currently, multiple databases exist for the annotation of circular RNAs, providing descriptions of their genomic features, FASTA sequences, predicted microRNA targets and RNA-binding protein interactions. Despite the availability of these resources, annotation remains cumbersome. Conflicting identif...
Barry Digby, S. Finn, P. Ó. Broin· Bioinformatics Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.